Article
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
European journal of haematology - 1 Dec 2015
Murai Kazunori, Akagi Tomoaki, Shimosegawa Kenji, Sugawara Tomohiro, Ishizawa Kenichi, Ito Shigeki, Murai Keiko, Motegi Mutsuhito, Yokoyama Hisayuki, Noji Hideyoshi, Tajima Katsushi, Kimura Jun, Chou Takaaki, Ogawa Kazuei, Harigae Hideo, Kubo Kohmei, Oba Koji, Sakamoto Junichi, Ishida Yoji
Abstract excerpt
BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of dasatinib in Japanese patients with imatinib-resistant or imatinib-intolerant chronic myeloid leukemia (CML). METHODS: From 2009 to 2011, 54 CML-chronic phase (CP) patients with resistance (n = 40) or intolerance (n = 25) to imatinib were registered to undergo dasatinib treatment. Eleven patients showed both resistance and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.